drugset / Trial / NCT00739453

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

NCT00739453

Phase 1 Completed 95 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

Timeline

Start
2008-10-23
Primary completion
2012-03-03
Completion
2012-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject linsitinib Small molecule Oral
Background Erlotinib Small molecule Oral

Indications